首页> 外文期刊>Journal of computer assisted tomography >Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
【24h】

Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.

机译:常规和抗血管生成化学疗法治疗结直肠癌的肝转移:肝电脑断层扫描灌注和磁共振扩散加权成像评估。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: The objectives of the study were to determine whether perfusion computed tomography (CT-p) and magnetic resonance diffusion-weighted imaging (MR-DWI) can allow evaluation of the effects of chemotherapy combined with antiangiogenetic treatment on liver metastases in patients with advanced colorectal cancer and to determine if changes in CT-p and MR-DWI correlate with the response to therapy as assessed by conventional Response Evaluation Criteria in Solid Tumors (RECIST). METHODS: Eighteen patients with liver metastases from colorectal cancer underwent CT-p and MR-DWI before and 6 months after chemotherapy and antiangiogenetic treatment. Lesions were classified according to RECIST criteria (complete response [CR], partial response [PR], stable disease [SD], and progressive disease) and calculations of CT-p parameters including blood flow (BF), blood volume (BV), capillary permeability (CP), and MR-DWI apparent diffusion coefficient (ADC) values were performed; RECIST, CT-p, and MR-DWI measurements at baseline and follow-up were tested for statistically significant differences using the paired-samples t test. Baseline and follow-up perfusion parameters of the lesions were also compared on the basis of therapy response assessed by RECIST criteria using independent-samples t test. P < 0.05 was considered indicative of a statistically significant difference for all statistical test. RESULTS: Six patients (6/18; 33.3%) were classified as PR (), and the remaining 12 (12/18; 66.7%) were classified as SD. On a per-lesion basis, 2 (2/32; 6.3%) cannot be identified at follow-up, 6 (6/32; 18.8%) showed a decrease in size of more than 30%, and 24 (24/32; 75%) were substantially stable in size. No cases of progressive disease were demonstrated at follow-up. No statistically significant differences were demonstrated between PR, CR, and SD lesions for BF (P = 0.19), BV (P = 0.14), and ADC (P = 0.68) measurements, whereas CP was significantly higher in CR and PR lesions (P = 0.038). Considering differences between baseline and follow-up values, no statistically significant differences were noted between PR and CR lesions versus SD lesions for CT-p values (BF: P = 0.77; BV: P = 0.15; CP: P = 0.64). A statistically significant difference between PR and CR lesions and SD lesions was noted for ADC values (P = 0.047). CONCLUSION: Both CT-p and MR-DWI can detect therapy-induced modifications in lesion vascularization before significant changes in size are evident.
机译:目的:本研究的目的是确定灌注计算机断层扫描(CT-p)和磁共振扩散加权成像(MR-DWI)是否可以评估化疗联合抗血管生成治疗对晚期肝转移的效果结肠直肠癌,并确定CT-p和MR-DWI的变化是否与对治疗的反应相关,如常规实体肿瘤反应评估标准(RECIST)所评估的那样。方法:18例大肠癌肝转移患者在化疗和抗血管生成治疗之前和之后6个月接受了CT-p和MR-DWI治疗。根据RECIST标准(完全缓解[CR],部分缓解[PR],稳定疾病[SD]和进行性疾病)以及计算CT-p参数(包括血流量(BF),血容量(BV),进行了毛细血管渗透性(CP)和MR-DWI表观扩散系数(ADC)值;使用配对样本t检验对基线和随访时的RECIST,CT-p和MR-DWI测量值进行统计学显着性检验。还基于RECIST标准使用独立样本t检验评估的治疗反应,比较了病变的基线和后续灌注参数。 P <0.05被认为是所有统计学检验的统计学差异。结果:6例(6/18; 33.3%)被分类为PR(),其余12例(12/18; 66.7%)被分类为SD。在每个病灶的基础上,无法发现2(2/32; 6.3%),6(6/32; 18.8%)的病灶缩小超过30%,24(24/32) ; 75%)的尺寸基本稳定。随访中未发现进行性疾病病例。在BF(P = 0.19),BV(P = 0.14)和ADC(P = 0.68)测量的PR,CR和SD病变之间未显示统计学显着差异,而CR和PR病变的CP显着更高(P = 0.038)。考虑到基线和随访值之间的差异,在PR和CR病变与SD病变之间CT-p值之间没有统计学上的显着差异(BF:P = 0.77; BV:P = 0.15; CP:P = 0.64)。对于ADC值,PR和CR病变与SD病变之间存在统计学上的显着差异(P = 0.047)。结论:CT-p和MR-DWI均可在明显改变大小之前检测出治疗引起的病变血管形成的改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号